Kailera Therapeutics
Phase 3Kailera Therapeutics is developing a broad and differentiated portfolio of clinical-stage injectable and oral GLP-1 therapies for clinical obesity, chronic weight management and related conditions.
Founded
2022
Focus
RNA & Gene TherapySmall Molecules
About
Kailera Therapeutics is developing a broad and differentiated portfolio of clinical-stage injectable and oral GLP-1 therapies for clinical obesity, chronic weight management and related conditions.
Company Info
TypePrivate
Founded2022
LocationSan Francisco, United States
StagePhase 3
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile